Navigation Links
Nektar Therapeutics Repurchases $100 Million of Convertible Debt and Reports Third Quarter 2008 Financial Results
Date:11/6/2008

e risk that the sale of the company's pulmonary business assets to Novartis Pharmaceuticals Corporation may not close or the closing may be delayed, (v) the company's patent applications for its proprietary or partner product candidates may not issue, patents that have issued may not be enforceable, or intellectual property licenses from third parties may be required in the future; and (vi) the outcome of any existing or future intellectual property or other litigation related to the company's proprietary product candidates or complex commercial agreements. Other important risks and uncertainties are detailed in the company's reports and other filings with the Securities and Exchange Commission, including its most recent Quarterly Report on Form 10-Q. Actual results could differ materially from the forward-looking statements contained in this press release. The company undertakes no obligation to update forward-looking statements, whether as a result of new information, future events or otherwise.

Stephan Herrera, 415-488-7699

sherrera@nektar.com

Jennifer Ruddock, 650-631-4954

jruddock@nektar.com

NEKTAR THERAPEUTICS

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(In thousands, except per share information)

Unaudited Unaudited

Three-Months Ended Nine-Months Ended

September 30, September 30,

2008 2007 2008 2007

Revenue:

Product sales and royalties $9,474 $37,497 $28,855 $159,818

Contract research 11,965 18,824 32,977 47,436

Total revenue 21,439 56,321 61,832 207,254

Ope
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9

Related medicine news :

1. Nektar to Announce Financial Results for the Third Quarter of 2008 on Thursday, November 6, 2008 After Close of U.S.-Based Financial Markets
2. Nektar Therapeutics Announces Second Quarter 2008 Results
3. Nektar Therapeutics Names Randall Moreadith, M.D., Ph.D. Senior Vice President, Drug Development and Chief Development Officer
4. Nektar Therapeutics Announces First Quarter 2008 Results
5. FDA Approval of Cimzia(R) for Crohns Disease Represents Latest Milestone for Nektars PEGylation Technology Platform
6. Nektar Therapeutics Announces Fourth Quarter and Year-End 2007 Financial Results
7. Nektar to Announce 2007 Year-End Financial Results on Wednesday, February 27, 2008, After Close of U.S.-Based Financial Markets
8. Nektar Therapeutics President and CEO, Howard W. Robin, to Present at Merrill Lynch 19th Global Pharmaceutical, Biotechnology & Medical Device Conference in New York City
9. Nektar Announces Agreement With Baxter to Develop New PEGylated Therapeutics for Hemophilia
10. Nektars Leading PEGylation and Pulmonary Technology Platforms Featured at R&D Day in New York
11. Nektar Therapeutics Announces Third Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2009)... community, in cooperation with the Greater VA Healthcare System in West ... attendance is expected to soar to more than 5,000 veterans, active ... ... (PRWEB) December 6, 2009 -- Volunteer organizations and members of the ... Los Angeles, will once again create a holiday party. This year,s ...
(Date:12/5/2009)... 5 The first Football,for Hope Centre in ... its doors,today (5 December 2009). FIFA President Joseph ... Zille, 2010 FIFA World Cup Organising Committee,South Africa ... Kirsten Nematandani and Executive Mayor of the City ...
(Date:12/5/2009)... advanced Technology Center helps companies develop and test their cleaning processes. ... a variety of industries and solve problems for customers relating to ... ... December 5, 2009 -- Midbrook, Inc , a Jackson, MI-based ...
(Date:12/4/2009)... Care Investment Trust Inc. (NYSE: CRE ... Directors has declared a dividend of $0.17 per share of common ... common shareholders of record on December 14, 2009. ... Inc. is a real estate investment and finance company investing in ...
(Date:12/4/2009)... America, Inc. ("HTA"), a self-managed, non-traded, real estate investment ... agreement to acquire a three building medical office portfolio ... Wayne, Indiana for approximately $20,500,000. The closing of ... number of conditions. ,, The approximately 92,500 square foot ...
Breaking Medicine News(10 mins):Health News:17th Annual Event Honoring 5,000 + Veterans, Military Personnel to Include Real Life “Heroes” 2Health News:17th Annual Event Honoring 5,000 + Veterans, Military Personnel to Include Real Life “Heroes” 3Health News:Opening of First Football for Hope Centre Heralds a New Dawn for Khayelitsha 2Health News:Opening of First Football for Hope Centre Heralds a New Dawn for Khayelitsha 3Health News:Midbrook Lab Testing Provides Results for Cleaning Process Develop and Verification 2Health News:Midbrook Lab Testing Provides Results for Cleaning Process Develop and Verification 3Health News:Care Investment Trust Inc. Declares Quarterly Dividend of $0.17 Per Share 2Health News:Healthcare Trust of America, Inc. Executes Agreement to Acquire a 92,500 Square Foot Medical Office Portfolio Located in Texas and Indiana 2
... The Minnesota Nurses,Association (MNA) announced today their endorsement ... Representatives, Congressional District 2., "As a veteran of ... and,informed advocate we need in Congress for meeting the ... Chair, Tom Kelly, RN.,"With his unequivocal support of the ...
... regulation of serotonin triggered sudden death in mice, researchers report, ... in the regulation of the brain chemical serotonin may be ... research suggests. , Reporting in the July 4 issue of ... serotonin levels in a mouse model resulted in sudden death ...
... condition that unexpectedly and unexplainably takes the lives of seemingly ... researchers of the European Molecular Biology Laboratory in Monterotondo, Italy, ... cot death, which remains the leading cause of death during ... published in this week,s issue of Science , reveals ...
... Dr. Thomas Hassell, former,global vice president of ... has joined IAVI as vice president for vaccine ... IAVI,s product development efforts,that are aimed at rapidly ... vaccine discovery programs., Dr. Hassell is trained ...
... from wildfires poses lethal health hazards to people ... respiratory problems such,as asthma, emphysema, and bronchitis and ... precautions during this time and call their,physician immediately ... diseases are at risk during this time," said,Norman ...
... THE IMPACT OF ... TECHNOLOGY IN HEALTHCARE ... PLANO, TX, July 3 Edition 20, Host: Dr. Kevin ... William Stead, Associate Vice Chancellor for,Strategy/Transformation & Chief Information Officer Vanderbilt ...
Other Medicine News:Health News:Minnesota Nurses Association Endorses Steve Sarvi for Congress 2Health News:SIDS Linked to Brain Chemical Dysfunction 2Health News:SIDS Linked to Brain Chemical Dysfunction 3Health News:New research sheds light on the molecular basis of crib death 2Health News:Leading Vaccine Expert Joins IAVI 2Health News:Leading Vaccine Expert Joins IAVI 3Health News:American Lung Association Urges People Living Near Wildfires to Protect Themselves Against Staggering Levels of Unhealthy Air Pollution 2Health News:American Lung Association Urges People Living Near Wildfires to Protect Themselves Against Staggering Levels of Unhealthy Air Pollution 3Health News:HEALTHCARE TECH AND THE WORLD: A MACRO PERSPECTIVE ON HOW TECHNOLOGY WILL IMPACT HEALTHCARE IN THE FUTURE 2Health News:HEALTHCARE TECH AND THE WORLD: A MACRO PERSPECTIVE ON HOW TECHNOLOGY WILL IMPACT HEALTHCARE IN THE FUTURE 3
(Date:12/4/2009)... WASHINGTON, Dec. 4 Chemistry World recently highlighted ... Research and Manufacturers of America ( PhRMA ) that ... and related conditions. ,, The report found that ... antivirals. These drugs are either in human clinical trials or ...
(Date:12/4/2009)... Inc., a wholly-owned subsidiary of Volcano Corporation (Nasdaq: ... testing of a novel integrated light source architecture for ... design raises the bar on imaging speed and overcomes ... light sources. This approach to optical engines builds ...
(Date:12/4/2009)... ("NWBT" or the "Company") (OTC Bulletin Board: NWBO) announced ... allowed its patent application on a system for automation ... Company,s DCVax® therapeutic cancer vaccines. These initial manufacturing ... dendritic cells (which are the critical ingredient) in the ...
Breaking Medicine Technology:U.S. Pharmaceutical Companies Developing 97 New Drugs and Vaccines to Fight HIV/AIDS 2Axsun Technologies, A Wholly-Owned Subsidiary of Volcano Corporation, Announces Breakthrough Integrated Light Source Architecture for Optical Coherence Tomography (OCT) Imaging 2Axsun Technologies, A Wholly-Owned Subsidiary of Volcano Corporation, Announces Breakthrough Integrated Light Source Architecture for Optical Coherence Tomography (OCT) Imaging 3Axsun Technologies, A Wholly-Owned Subsidiary of Volcano Corporation, Announces Breakthrough Integrated Light Source Architecture for Optical Coherence Tomography (OCT) Imaging 4Axsun Technologies, A Wholly-Owned Subsidiary of Volcano Corporation, Announces Breakthrough Integrated Light Source Architecture for Optical Coherence Tomography (OCT) Imaging 5Northwest Biotherapeutics Receives Approval of US Patent for Cost Saving Automation of High-Concentration DCVax(R) Manufacturing 2Northwest Biotherapeutics Receives Approval of US Patent for Cost Saving Automation of High-Concentration DCVax(R) Manufacturing 3Northwest Biotherapeutics Receives Approval of US Patent for Cost Saving Automation of High-Concentration DCVax(R) Manufacturing 4Northwest Biotherapeutics Receives Approval of US Patent for Cost Saving Automation of High-Concentration DCVax(R) Manufacturing 5AEterna Zentaris to Complete Phase 3 Clinical Trial of Macimorelin 28AEZS 130 29 as First Oral Diagnostic Test for Growth Hormone Deficiency 14520 1AEterna Zentaris to Complete Phase 3 Clinical Trial of Macimorelin 28AEZS 130 29 as First Oral Diagnostic Test for Growth Hormone Deficiency 14520 2AEterna Zentaris to Complete Phase 3 Clinical Trial of Macimorelin 28AEZS 130 29 as First Oral Diagnostic Test for Growth Hormone Deficiency 14520 3NovaBay Pharmaceuticals Expands Management Team 3B Names Mark Anderson Ph D as Chief Scientific Officer 5549 1NovaBay Pharmaceuticals Expands Management Team 3B Names Mark Anderson Ph D as Chief Scientific Officer 5549 2NovaBay Pharmaceuticals Expands Management Team 3B Names Mark Anderson Ph D as Chief Scientific Officer 5549 3ERISAclaim com Announced Free ERISA Webinar for Healthcare Overpayment Dispute and Claim Denials in Response to Increasing High Demand from the 246 T 59724 1ERISAclaim com Announced Free ERISA Webinar for Healthcare Overpayment Dispute and Claim Denials in Response to Increasing High Demand from the 246 T 59724 2ERISAclaim com Announced Free ERISA Webinar for Healthcare Overpayment Dispute and Claim Denials in Response to Increasing High Demand from the 246 T 59724 3ERISAclaim com Announced Free ERISA Webinar for Healthcare Overpayment Dispute and Claim Denials in Response to Increasing High Demand from the 246 T 59724 4
... Service Members, Other AmericansWASHINGTON, May 27 The Department ... of an advanced artificial arm that easily allows those ... or hold a pencil."This arm is a high-tech example ... design, and clinical use of artificial limbs to meet ...
... Kinex Pharmaceuticals will present results from a Phase 1 ... in Orlando, on May 29, 2009. The study was ... and Fox Chase Cancer Center. Dr. Alex Adjei, the ... of a phase I trial of KX2-391, a novel non-ATP ...
Other Medicine Technology:VA Studies Advanced Prosthetic Arm 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: